IMGN Live signaler | Maksimer profitt med Getagraph.com

SELG 116429 min ago

@ $31.23

Utstedt: 8 feb 2024 @ 15:30

Avkastning: 0.02%

Forrige signal: feb 7 - 21:55

Forrige signal: Kjøp

Avkastning: 5.67 %

Live Chart Being Loaded With Signals

Commentary (9 feb 2024 @ 21:58):

Stats
Dagens volum	19.31M
Gjennomsnittsvolum	8.29M
Markedsverdi	8.73B
EPS	$0 ( 2024-04-26 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-111.55
ATR14	$0.306 (0.98%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-12	Mitchell Dean J	Sell	103 000	Common Stock
2024-02-12	Mitchell Dean J	Sell	13 090	Restricted Stock Unit
2024-02-12	Mitchell Dean J	Sell	142 667	Deferred Share Unit
2024-02-12	Mitchell Dean J	Sell	10 000	Stock Option (Right to Buy)
2024-02-12	Mitchell Dean J	Sell	10 000	Stock Option (Right to Buy)

INSIDER POWER
-100.00
Last 100 transactions
Buy: 0 \| Sell: 8 781 240

Volum Korrelasjon

Lang: 0.24 (neutral)

Kort: 0.25 (neutral)

Signal:(82.516) Neutral

ImmunoGen Inc Korrelasjon

10 Mest positive korrelasjoner
HOL	0.945
IRBT	0.93
SLNG	0.929
RTPY	0.927
KBSF	0.926
LGMK	0.92
RPID	0.919
FIBK	0.917
GBCI	0.917
LYEL	0.917

10 Mest negative korrelasjoner
AEAE	-0.941
ENTF	-0.941
CCTS	-0.941
HORI	-0.939
GHIX	-0.938
FIAC	-0.938
XPAX	-0.938
NECB	-0.936
ADAL	-0.935
ACAB	-0.935

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

ImmunoGen Inc Korrelasjon - Valuta/Råvare

-0.22
( neutral )

0.51
( weak )

0.55
( weak )

-0.04
( neutral )

-0.02
( neutral )

0.26
( neutral )

ImmunoGen Inc Økonomi

Annual	2022
Omsetning:	$108.78M
Bruttogevinst:	$108.61M (99.84 %)
EPS:	$-0.880

FY	2022
Omsetning:	$108.78M
Bruttogevinst:	$108.61M (99.84 %)
EPS:	$-0.880

FY	2022
Omsetning:	$108.78M
Bruttogevinst:	$108.61M (99.84 %)
EPS:	$-0.880

FY	2020
Omsetning:	$132.30M
Bruttogevinst:	$17.71M (13.38 %)
EPS:	$-0.250

Financial Reports:

No articles found.

ImmunoGen Inc

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.